Investors & Funding
Advancing precision oncology through AI for clinical care and drug development
Curenetics is commercialising Cure-io, an AI-enabled precision oncology platform designed to support better decision-making across two high-value areas of the oncology market.
In healthcare, Cure-IO is being developed for use by oncologists as an integrated platform within hospital PHR and EHR systems, helping bring patient-specific clinical and molecular insight into routine workflow. In parallel, Curenetics will offer Cure-io to pharmaceutical companies and CROs to support biomarker discovery, patient stratification and more informed oncology development decisions.
By applying AI to complex multimodal data, Curenetics aims to help improve how oncology decisions are made, both at the point of care and across the drug development pathway.
Investment case
Curenetics is positioned at the intersection of precision oncology, artificial intelligence and translational medicine, addressing major unmet needs in both healthcare delivery and oncology R&D.
The company’s proposition is built around two complementary commercial pathways. The first is the use of Cure-IO in clinical practice, where oncologists need better ways to interpret complex patient data and support treatment decisions. The second is the use of the platform by pharma and CRO partners seeking deeper insight into treatment response, patient selection and clinical development strategy. Together, these pathways create the potential for broad market relevance and multiple routes to value creation.
Healthcare application
Cure-IO is designed for use by healthcare professionals, particularly oncologists, as part of an integrated digital clinical environment. By connecting with hospital PHR and EHR systems, the platform is intended to fit within existing workflow rather than sit outside it as a separate research tool.
The goal is to provide clinicians with AI-enabled, patient-specific insight generated from complex clinical and molecular data, supporting more informed decision-making in precision oncology. In a treatment landscape where response can vary significantly between patients, better interpretation of available data has the potential to improve confidence, consistency and relevance in care planning.
Pharma and CRO application
Curenetics will also offer Cure-IO to pharmaceutical companies and CROs as a platform to support oncology research and development.
In this setting, the platform is intended to help partners extract greater value from complex datasets, support biomarker discovery, improve patient stratification and generate insight into likely treatment response. These capabilities are highly relevant in oncology development, where clinical attrition remains high and understanding patient heterogeneity is critical to trial design, translational strategy and commercial success.
By supporting more informed development decisions, Cure-IO is designed to address both scientific and economic challenges within cancer drug development.
Technology and science
Cure-io is an AI-enabled platform built to analyse complex multimodal data in oncology. Its purpose is to identify clinically and biologically relevant patterns that may not be easily visible through conventional analysis alone.
The scientific rationale behind the platform is straightforward. Cancer is highly heterogeneous, and treatment response is influenced by a wide range of interacting biological and clinical factors. As the volume and complexity of patient data continue to grow, there is a clear need for tools that can help transform that data into usable insight. Curenetics is developing Cure-io to meet that need with a platform designed to support both clinical application and life sciences partnership models.
Thoughtfully crafted to elevate what matters most.
Market opportunity
Curenetics is targeting two important and growing markets.
The first is the healthcare market, where the continued shift towards precision medicine is increasing demand for tools that can support more personalised oncology decision-making and integrate into hospital systems.
The second is the pharma and CRO market, where pressure remains high to improve efficiency in oncology R&D, strengthen biomarker strategies and reduce the risk of costly development failure. A platform that can contribute to both areas has the potential to capture value across a broad section of the oncology ecosystem.
Thoughtfully crafted to elevate what matters most.
Business model
Curenetics is building a business model around the commercial deployment of Cure-IO in both healthcare and life sciences settings.
Within healthcare, value will come from platform adoption in clinical environments through integration with hospital PHR and EHR systems. Within pharma and CRO markets, value will come from partnerships and commercial engagements focused on research, development and translational oncology applications.
This dual-market approach is intended to create diversified commercial opportunities while keeping the company focused on a single core platform and a clearly defined strategic area of need.
Thoughtfully crafted to elevate what matters most.
Why Curenetics
Curenetics brings together a strong market opportunity, a science-led platform and a commercial model aligned to real-world oncology challenges.
The company is focused on solving meaningful problems in both patient care and drug development. Its platform is designed not only to generate insight, but to do so in settings where that insight can have practical value, whether in the clinic or in oncology R&D. This combination of clinical relevance, technical ambition and commercial breadth underpins the long-term opportunity for investors.
Thoughtfully crafted to elevate what matters most.
Leadership and growth
Curenetics is building a business around a clear strategic vision: to make advanced AI insight more usable and more valuable in oncology.
As the company grows, its focus will be on platform development, validation, partnership building and commercial execution across its two core markets. With the right support, Curenetics has the potential to establish itself as a meaningful player in the future of precision oncology.
Thoughtfully crafted to elevate what matters most.
Get In Touch
If you're interested in working with us, complete the form with a few details about your project. We'll review your message and get back to you within 48 hours.